线粒体功能障碍在脓毒症获得性无力中作用的研究进展
脓毒症获得性无力(SAW)是危重患者常见并发症,机制认识和治疗干预均存在显著缺口。SAW不仅延长机械通气时间和住院时间,还与死亡率升高密切相关,存活者出院后常长期存在躯体功能障碍、生活质量下降。新出现的证据提示,持续线粒体功能障碍可能是SAW发生发展的关键病理生理基础,主要涵盖线粒体质量控制失调、氧化磷酸化受损、氧化应激加剧、Ca2+稳态破坏及它们介导的多种肌纤维损伤五个方面。本文系统阐述线粒体功能障碍在SAW发病中的核心作用,并探讨靶向线粒体的潜在治疗策略,包括减轻线粒体氧化应激、优化营养支持和补充肌源性间充质干细胞。
要点
- SAW是危重患者常见并发症,不仅延长机械通气时间和住院时间,还与死亡率升高密切相关。
- 存活的SAW患者出院后常长期存在躯体功能障碍,导致生活质量下降。
- 新出现的证据提示,持续线粒体功能障碍可能是SAW发生发展的关键病理生理基础。
- 线粒体功能障碍参与SAW主要涵盖五个方面:线粒体质量控制失调、氧化磷酸化受损、氧化应激加剧、Ca2+稳态破坏及它们介导的多种肌纤维损伤。
- 靶向线粒体的潜在治疗策略包括减轻线粒体氧化应激、优化营养支持和补充肌源性间充质干细胞,作者强调线粒体靶向治疗在改善脓毒症患者结局中的转化价值。
适用人群与场景
- 危重患者,尤其是脓毒症患者(SAW为脓毒症后常见并发症)。
研究设计与关键结果
- 本文为综述,系统阐述线粒体功能障碍在SAW发病中的核心作用,涵盖线粒体质量控制失调、氧化磷酸化受损、氧化应激加剧、Ca2+稳态破坏及它们介导的多种肌纤维损伤五个方面。
- 探讨靶向线粒体的潜在治疗策略,包括减轻线粒体氧化应激、优化营养支持和补充肌源性间充质干细胞。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,线粒体功能障碍可能是SAW发生发展的关键病理生理基础,靶向线粒体的治疗在改善脓毒症患者结局中具有转化价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis-acquired weakness (SAW) is a common complication in critically ill patients, yet significant gaps remain in both mechanistic understanding and therapeutic interventions for this condition. SAW not only prolongs the duration of mechanical ventilation and hospitalization but is also closely associated with increased mortality. Even if these SAW patients survive, they often experience long-term physical dysfunction after hospital discharge, leading to diminished quality of life. Emerging evidence suggests that sustained mitochondrial dysfunction may constitute a pivotal pathophysiological basis for the development and progression of SAW, primarily encompassing five key aspects: dysregulated mitochondrial quality control (MtQC), impaired oxidative phosphorylation (OXPHOS), exacerbated oxidative stress, disrupted Ca2+; homeostasis, and their mediation of diverse myofiber injuries. This article systematically elucidates the central role of mitochondrial dysfunction in the pathogenesis of SAW. Furthermore, we explore potential therapeutic strategies targeting mitochondrial function, including mitigating mitochondrial oxidative stress, optimizing nutritional support, and supplementing with muscle-derived mesenchymal stem cells. These insights provide a critical theoretical framework for understanding SAW mechanisms and developing clinical interventions, with particular emphasis on the translational value of mitochondrial-targeted therapies in improving outcomes for septic patients.
参考来源
- Chang X, Guo Z, Fang J, et al. [Research advances on the role of mitochondrial dysfunction in sepsis-acquired weakness]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41331895. doi:10.3760/cma.j.cn121430-20250724-00700
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。